BE680956A - - Google Patents
Info
- Publication number
- BE680956A BE680956A BE680956DA BE680956A BE 680956 A BE680956 A BE 680956A BE 680956D A BE680956D A BE 680956DA BE 680956 A BE680956 A BE 680956A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- chloro
- products
- weight
- combination
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 3
- 230000001077 hypotensive effect Effects 0.000 claims description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 5
- 229960002155 chlorothiazide Drugs 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 229950009414 pempidine Drugs 0.000 description 4
- XULIXFLCVXWHRF-UHFFFAOYSA-N 1,2,2,6,6-pentamethylpiperidine Chemical compound CN1C(C)(C)CCCC1(C)C XULIXFLCVXWHRF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- WRYZEGZNBYOMLE-UHFFFAOYSA-N hydracarbazine Chemical compound NNC1=CC=C(C(N)=O)N=N1 WRYZEGZNBYOMLE-UHFFFAOYSA-N 0.000 description 3
- 229950002598 hydracarbazine Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- AAFNEINEQRQMTF-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;1,2,2,6,6-pentamethylpiperidine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1C(C)(C)CCCC1(C)C AAFNEINEQRQMTF-LREBCSMRSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- -1 ma- EMI2.4 leate Chemical compound 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR17181A FR4736M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1965-05-14 | 1965-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE680956A true BE680956A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-11-14 |
Family
ID=8578827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE680956D BE680956A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1965-05-14 | 1966-05-12 |
Country Status (3)
-
1965
- 1965-05-14 FR FR17181A patent/FR4736M/fr not_active Expired
-
1966
- 1966-05-12 NL NL6606530A patent/NL6606530A/xx unknown
- 1966-05-12 BE BE680956D patent/BE680956A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL6606530A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-11-15 |
| FR4736M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1967-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2246289C (fr) | Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique | |
| EP0678026B1 (fr) | Application de la carbamazepine et de l'oxcarbazepine dans le traitement de la maladie de parkinson et des syndromes parkinsoniens | |
| FR2804604A1 (fr) | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac | |
| Skaare et al. | Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU) | |
| DE3428729A1 (de) | Mittel zur verhinderung oder inhibierung einer alveolaeren knochenresorption | |
| BE680956A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3785689T2 (de) | Verwendung von prostaglandin-biosynthese-hemmer. | |
| JP2001172171A (ja) | 熱ショック蛋白質誘導剤 | |
| DE19849737A1 (de) | Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen | |
| EP0959892B1 (fr) | Utilisation de pvp ou povidone pour diminuer le gonflement intestinal | |
| EP0966276B1 (fr) | Utilisation d'agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants | |
| CA1059913A (fr) | Compositions pharmaceutiques | |
| CA1226817A (fr) | COMPOSITION PHARMACEUTIQUE CONSTITUEE D'UNE PART, A TITRE DE PRINCIPE ACTIF, PAR LA 9.alpha., 11.beta.-DICHLORO 16.alpha.-METHYL 21-OXYCARBONYLDICYCLOHEXYL METHTLOXY PREGNA-1,4-DIENE 3,20-DIONEET D'AUTRE PART, PAR UN EXCIPIENT PHARMACEUTIQUE INERTE APTE A PERMETTRE | |
| EP1496884B1 (fr) | Association d'un antithrombotique et d'aspirin et son utilisation pour le traitement des maladies thrombotiques atherosclereuses | |
| FR2641971A1 (fr) | Composition pharmaceutique antihypertensive associant le benazepril et un diuretique thiazidique | |
| EP1115399B1 (fr) | Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour la fabrication d'un medicament pour traiter les glomerulonephrites chroniques | |
| Ganesan et al. | Polyphloretin phosphate temporarily potentiates prostaglandin E2 on the rat fundus, probably by inhibiting PG15‐hydroxydehydrogenase | |
| EP0396474B1 (en) | Use of aromatical aminoalcoxy derivatives in the treatment of cerebrovascular disorders | |
| BE708434A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE19532714A1 (de) | Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden | |
| FR2564831A1 (fr) | Nouveaux derives des acides aroyl- ou hydroaroyl n-alcoyl pyrrolyl-2 carboxyliques et nouvelles compositions pharmaceutiques a action immuno-suppressive | |
| FR2650502A1 (fr) | Nouvelle forme galenique orale ameliorant la biodisponibilite | |
| BE1009698A3 (fr) | Nouvelle utilisation de composes agonistes 3-adrenergiques. | |
| FR2464071A1 (fr) | Preparation pharmaceutique a base de dihydro-ergotamine et d'heptaminol | |
| FR2504008A1 (fr) | Preparation pharmaceutique a base d'un melange de n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine et d'un diuretique |